FGF21 and metabolic dysfunction-associated steatohepatitis: In the phase 2 ENLIVEN trial, pegozafermin (an FGF21 analogue) significantly improved liver fibrosis without worsening MASH in biopsy-confirmed cases, supporting its progression to phase 3 trials [255].